side effects of glp 1 drugs Part 2 a 3-Part Series; GLP-1 Medications for Weight Loss Peptide/GLP-1 Complications: 11 Hidden Risks
Description
As the new obesity pharmacotherapies will lead up to 1525% mean WL, intensive lifestyle interventions may provide small additional WL benefit to these treatments [11, 106]
10.1002/pds.668 77 WhartonS.DaviesM.DickerD.LingvayI.MosenzonO.RubinoD
A., Duran S., Kim D., et al., A Comparison of TwiceDaily Exenatide and Biphasic Insulin Aspart in Patients With Type 2 Diabetes Who Were Suboptimally Controlled With Sulfonylurea and Metformin: A NonInferiority Study, Diabetologia 50 (2007): 259267
Compounded medications are different from FDA-approved generics but provide affordable access to the same active ingredient now rather than waiting 10-15 years
Other combinations of entero-pancreatic hormones including cagrisema (GLP-1/amylin RA) and the triple agonist retatrutide (GLP-1/GIP/glucagon RA) have also progressed to phase 3 trials as obesity treatments and early data suggests that may lead to even greater WL than tirzepatide
encourage patients to combine medication with diet, exercise and behavioral support
